Cagrilintide vs Retatrutide
Mechanisms differ (amylin analogue vs triple incretin/glucagon agonism); evidence strength and development stage must be compared, not declared a winner.
| Attribute | Cagrilintide | Retatrutide |
|---|---|---|
| Human evidence | Cagrilintide has randomized Phase II evidence and a Phase IIIa monotherapy arm within REDEFINE 1; the dedicated RENEW Phase 3 monotherapy programme is underway. | Retatrutide now has peer-reviewed Phase III human evidence in type 2 diabetes (TRANSCEND-T2D-1), alongside earlier randomized Phase II obesity and MASLD data. Obesity Phase III results are also emerging, but published and sponsor-reported evidence should be kept distinct. |
| Research focus | Obesity, appetite and weight-management research | Obesity, weight management, metabolic disease |
| Regulatory status | FDA states cagrilintide is not a component of an FDA-approved drug, has not been found safe and effective for any condition, and cannot be used in U.S. compounding under federal law. | Not FDA-approved as of this review; FDA states retatrutide has not been found safe and effective for any condition and cannot be used in US compounding. |
| Route / formulation | Trial evidence does not establish quality or equivalence of research-market material. | Evidence applies to trial-grade retatrutide, not to unverified research-market vials or pens. |
Why these are compared
These compounds appear in the weight & appetite evidence landscape, but they are not interchangeable. Cagrilintide is long-acting amylin analogue peptide studied in obesity, appetite and weight-management research; Retatrutide is tri-agonist peptide (gip/glp-1/glucagon receptor agonist) studied in obesity, weight management, metabolic disease. The purpose of this page is to compare the evidence base, not to recommend one compound over another.
Evidence maturity
Cagrilintide: Phase 3 monotherapy evidence and development; investigational / not FDA-approved.
Retatrutide: Multiple Phase 3 human trials; investigational.
The table above gives the fuller human-evidence, regulatory and formulation context. Open the individual profiles for study-level records, limitations and source provenance.
What this comparison can and cannot establish
No direct head-to-head outcome trial identified. Cross-study comparisons can be distorted by differences in population, route, formulation, dose, duration and endpoint. WhichPeps therefore does not turn indirect comparisons into a treatment recommendation or name a winner. A well-designed head-to-head human trial using comparable populations and clinically relevant outcomes would reduce uncertainty.